Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

CAR-T therapy: navigating the US reimbursement landscape

Reimbursement of personalised CAR-T therapies has proven to be a real issue for healthcare providers, insurers and US government agencies. The Centre for Medicare and Medicaid Services has recognised the need to increase its contribution in paying for CAR-T therapies with the aim of increasing patient access to these revolutionary treatments. Cambridge Consultants’ James Hallinan discusses the current US CAR-T reimbursement landscape, as well as the remaining challenges and barriers to patient access.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top